---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-006559"
form_type: "8-K"
ticker: "PROF"
cik: "0001628808"
company_name: "Profound Medical Corp."
filed_at: "2026-10-09T17:11:55+00:00"
generated_at: "2026-10-12T15:14:07.730095+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Profound Medical, Telix sign co-education deal pairing PSMA-PET imaging with TULSA-PRO therapy

## Summary
- Co-education agreement pairs Telix's PSMA-PET agents Gozellix and Illuccix with Profound's MRI-guided, incisionless TULSA-PRO platform in prostate care.
- Planned initiatives: medical society meetings, KOL programs, educational summits, speaker programs, webinars, clinical case studies and best-practice content.
- Profound is developing PSMA-PET-MR image fusion for a planned future Treatment Delivery Console software release; no financial terms were disclosed.
- CEO Arun Menawat cites increased access to urologists via Telix; Telix Precision Medicine CEO Kevin Richardson cites more personalized patient care.
- CTO Mathieu Burtnyk: ~85% of prostate cancers are multifocal while ~15% are unifocal; ~15-25% of patients are focal-ablation candidates.

## SEC filing metadata
- accession: 0001171843-26-006559
- form_type: 8-K
- ticker: PROF
- cik: 0001628808
- company_name: Profound Medical Corp.
- filed_at: 2026-10-09T17:11:55+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628808/000117184326006559/0001171843-26-006559-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628808/000117184326006559/f8k_100926.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-006559
- JSON: https://secwatch.observer/filing/0001171843-26-006559.json
- Plain text: https://secwatch.observer/filing/0001171843-26-006559.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.